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KEY PO INT S
l IPS-E is a simple and
robust prognostic
model for early-
stage CLL.
l IPS-E can be helpful in
patients’ counseling
and design of clinical
trials.
Most patients with chronic lymphocytic leukemia (CLL) are diagnosed with early-stage
disease and managed with active surveillance. The individual course of patients with early-
stage CLL is heterogeneous, and their probability of needing treatment is hardly antici-
pated at diagnosis. We aimed at developing an international prognostic score to predict
time to first treatment (TTFT) in patients with CLL with early, asymptomatic disease (In-
ternational Prognostic Score for Early-stage CLL [IPS-E]). Individual patient data from 11
international cohorts of patientswith early-stage CLL (n5 4933)were analyzed to build and
validate the prognostic score. Three covariates were consistently and independently
correlated with TTFT: unmutated immunoglobulin heavy variable gene (IGHV), absolute
lymphocyte count higher than 153 109/L, and presence of palpable lymph nodes. The IPS-E
was the sum of the covariates (1 point each), and separated low-risk (score 0), intermediate-risk (score 1), and high-risk
(score 2-3) patients showing a distinct TTFT. The score accuracy was validated in 9 cohorts staged by the Binet system
and 1 cohort staged by the Rai system. The C-index was 0.74 in the training series and 0.70 in the aggregate of
validation series. By meta-analysis of the training and validation cohorts, the 5-year cumulative risk for treatment start
was 8.4%, 28.4%, and 61.2% among low-risk, intermediate-risk, and high-risk patients, respectively. The IPS-E is a
simple and robust prognostic model that predicts the likelihood of treatment requirement in patients with early-stage
CLL. The IPS-E can be useful in clinical management and in the design of early intervention clinical trials. (Blood. 2020;
135(21):1859-1869)
Introduction
Chronic lymphocytic leukemia (CLL) is characterized by the re-
lentless accumulation of monoclonal B lymphocytes with a
distinct immunophenotype (ie, CD5, CD19, CD20, CD23) in
peripheral blood, bonemarrow, and lymphoid organs. CLL is the
most frequent form of leukemia in Western countries, where
0.6% of the population is diagnosed with this B-cell tumor during
their lifetime.1 In most instances, CLL is diagnosed in general
practice, and approximately 70% of patients present in an early
phase of the disease, with no anemia, no thrombocytopenia, and
no significantly enlarged lymph nodes or spleen.2
According to international guidelines, patients with asymp-
tomatic early-stage CLL should not be treated until disease
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progression occurs, and active surveillance remains the standard
for management.3-5 Indeed, different clinical trials enrolling patients
with early-stage CLL failed to show a survival benefit of early in-
tervention strategies based on chemo-chemoimmunotherapy.6-10
However, patients with early-stage CLL have a variable clinical
course. Some require treatment soon after diagnosis because of
development of cytopenia or bulky lymphadenopathy, whereas
others show a stable or a slowly progressive disease not requiring
treatment of decades.11 Because of this, the management of pa-
tients with early-stage CLL is challenging and shaped by un-
certainty. Of note, it is estimated thatmore than 400000 individuals
in Europe and the United States diagnosed with CLL are followed
by active surveillance.1,12 Unfortunately, there is no a specific,
simple, accurate, and widely accepted prognostic model to predict
the likelihood of disease progression, and hence need for therapy,
in patients with asymptomatic early-stage CLL.
The management of early, asymptomatic CLL may change in the
future if a survival benefit is proven by early intervention with
novel agents in patients who are at risk for impending pro-
gression to symptomatic disease requiring treatment.13 In this
new scenario, upfront identification of high-risk patients is
warranted. The objective of this study was to construct a simple,
robust, and validated predictor of disease progression and the
need for intervention in patients with asymptomatic early-
stage CLL.
Methods
Study design
This is a multicenter, international, retrospective, observational
study in which already-existing and coded health-related data
were further used (ClinicalTrials.gov identifier: NCT03436524).
We obtained the individual patient data sets from 11 cohorts,
including 8 series that were previously used to generate or
validate scoring systems in CLL (Tables 1 and 2).10,14-19 Inclusion
criteria were: presentation after 1996 confirmed by flow
cytometry3,4; Binet stage A at diagnosis, as defined by blood cell
count and physical examination3,4; and active surveillance as
initial management, defined by no treatment requirement within
the first 3 months after diagnosis. The Reporting Recommen-
dations for Tumor Marker Prognostic Studies (REMARK) criteria
were followed throughout the study.20 Patients provided in-
formed consent in accordance with local institutional review
board requirements and the Declaration of Helsinki. The ethics
committee approved the study (BASEC 2018-00341). Early-
stage CLL was defined according to the Binet system in 10 of
11 cohorts. Data of individual patients with early (Binet stage A)
disease managed with active surveillance policy were collected
from the CLL1 (ClinicalTrials.gov identifier: NCT00262782;
N5 547)9,18 and CLL7 (ClinicalTrials.gov identifier: NCT00275054;
N5 339) trials of the German CLL Study Group, and the O-CLL1
GISL trial (ClinicalTrials.gov identifier: NCT00917540;N5 312).15,19
The M.D. Anderson Cancer Center (N 5 1225),14 the University
of Eastern Piedmont (UEP; N5 333),17 the Barcelona (N5 355),19
the Brno University Hospital (Brno; N5 269),19 the Southampton
(N 5 226), and the Sapienza University (N 5 223) cohorts are
institutional consecutive series of newly presented and pro-
spectively observed patients with early (Binet stage A) disease.
Binet stage A patients’ data of the SCAN cohort (N 5 223) were
collected from the SCALE Scandinavian population-based
case-control study.16 The Mayo Clinic cohort (N 5 881) is an
institutional series of patients with early stage 0, I, and II disease
defined according to the Rai system.
Data analysis
We consecutively performed both uni- and multivariable anal-
yses using the full data set of the training cohort (UEP). Sub-
sequently, we analyzed the external validation data sets to
confirm the findings from the full-analysis data set. The study end
point was time to first treatment (TTFT), defined as the time
between presentation and start of first treatment of CLL because
of progression to symptomatic disease according to the National
Cancer Institute-Working Group/International Workshop on
Chronic Lymphocytic Leukemia guidelines (patients without a
documented event were censored at the date of last observation
or death).3,4 Nineteen baseline biomarkers, assessed within
1 month from initial presentation, were initially considered as
Table 1. Characteristics of the training cohort
Variable
UEP (N 5 333)
N % Missing
Age .65 years 208 62.4 —
Male sex 178 53.4 —
Palpable lymph nodes 68 20.4 —
Palpable spleen 20 6.0 —
Lymphocytes .15 3 109/L 65 19.5 —
Hb ,13 g/dL (male)/,12 g/dL (female) 39 11.7 —
Platelets ,150 3 109/L 46 13.8 —
B2M .3.5 mg/L 32 9.6 —
FISH normal 112 33.6 —
Del(13q) 168 50.4 —
Trisomy 12 59 17.7 —
Del(11q) 18 5.4 —
Del(17p) 19 5.7 —
Unmutated IGHV 92 27.6 —
TP53 mutation 24 7.2 —
ATM mutation 24 8.3 44
MYD88 mutation 18 5.4 4
NOTCH1 mutation 35 10.6 4
SF3B1 mutation 17 5.1 4
CLL-IPI
Low risk 182 54.7
Intermediate risk 94 28.2
High risk 45 13.5
Very high risk 12 3.6
B2M, b-2-microglobulin; Del, deletion; Hb, hemoglobin.
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covariates for construction of the prognostic index. These
covariates were clinical characteristics (age, sex, $1 palpable
lymph node with a diameter $1 cm and palpable spleen by
investigator’s physical examination),21 laboratory values (he-
moglobin level, platelet count, absolute lymphocyte count, and
b-2-microglobulin), cytogenetic abnormalities as assessed by
fluorescence in situ hybridization [FISH; del(17p), del(11q), tri-
somy 12, del(13q)], and gene mutations (immunoglobulin heavy
variable gene [IGHV], ATM, MYD88, NOTCH1, SF3B1, and
TP53). FISH was performed for assessing the t(11;14) in those
cases in which a diagnosis of mantle cell lymphoma could be
considered; patients harboring such translocations were ex-
cluded from the study. Continuous variables were categorized
by published thresholds (age, hemoglobin, platelet count, b-2-
microglobulin, IGHV identity)18,22-25 or by identifying the best
cutoff through recursive partitioning (absolute lymphocyte
count; supplemental Figure 1, available on the BloodWeb site).
Blood cell count was assessed by local laboratories. b-2-
microglobulin was assessed by local laboratories with the ex-
ception of the CLL1, CLL7, and SCAN cohorts for which the
information was provided centrally. FISH cytogenetics were
assessed locally, with the exception of the CLL1, CLL7, and
O-CLL1 cohorts, for which the information was provided cen-
trally and scored according to the laboratory cutoff. IGHV and
TP53 mutations were assessed by Sanger sequencing locally,
with the exception of CLL1, CLL7, andO-CLL1 cohorts, for which
the information was provided centrally. Mutations of ATM,
MYD88, NOTCH1, and SF3B1 were assessed in the training
cohort by targeted deep next-generation sequencing, using an
allele frequency of at least 10% for defining a positive result.26
For the validation data sets, only variables composing the final
model were included in the analyses. In the training and vali-
dation cohorts, minimal missing data were documented among
covariates used for development and validation of the prog-
nostic score. Therefore, no missing data imputation proce-
dures were used. All statistical tests were 2-sided. Statistical
significance was defined as P, .05. The analysis was performed
with the Statistical Package for the Social Sciences software
v.22.0 (Chicago, IL) and with R statistical package v3.4.1 (www.
r-project.org).
Development and validation of a score for TTFT
prognostication
Survival analysis was performed by the Kaplan-Meier method
and comparison between strata, using the log-rank test.27
Sensitivity analyses of TTFT were performed by considering
death without treatment as a competing risk and by using Gray’s
test for comparisons between strata.28,29 The adjusted associa-
tion between exposure variables and TTFT was estimated by
Cox regression.30 In the training cohort, Cox regression included
exposure variables showing an univariable association with
TTFT with a Bonferroni corrected P, .05 to account for multiple
testing. Backward elimination using likelihood ratio statistics with
selection criterion P, .05 was used to derive the final Coxmodel
to be validated. An elastic net penalized regressionmodel was fit
to the training set to exclude potential variable loss in the
backward selection procedure.31 The mixing parameter was
selected using 10-fold cross-validation. The ideal model was
selected as that corresponding to the largest value of the tuning
parameter, such that the error was within 1 standard error of the
minimum mean cross-validated error. The proportional hazard
assumption was assessed by plotting the smoothed Schoenfeld
residuals against time.32 The stability of the Cox model was
externally validated across the 9 Binet A validation cohorts. Only
variables independently and significantly associated with TTFT
in more than 50% of the validation cohorts were used to con-
struct the final score. We assigned a weighted-risk score to each
factor based on the regression parameters from the Cox re-
gression analysis. The score was defined as the sum of single-risk
parameters.18 We stratified patients in different risk groups by
recursive partitioning of the score.33 Two major steps were used
to derive the best decision tree: growing an initial tree under the
following constraints and stopping rules: i) split criteria of P, .01
according to the log-rank test, ii) more than 20 patients in a node
to be considered for splitting, and iii) more than 10 patients in a
terminal node; and applying a pruning algorithm based on the
complexity parameter (cp . 0.01). Model discrimination was
computed using the Harrel’s C-index.34 The 9 Binet A validation
cohorts were meta-analyzed to interpolate the validation series
in a single plot. TTFT and corresponding 95% confidence in-
tervals (95% CIs) were estimated in each of the Binet A validation
cohorts at 6-month intervals. At each point, a random-effect
model was used to provide a meta-analytic estimate of TTFT and
corresponding 95% CIs across the Binet A validation cohorts.
Survival curves were plotted by fitting a cubic smoothing spline
to the estimates of TTFT and the respective 95% CIs, using a
smoothing parameter of 0.6. A fixed-effect model was used for
the meta-analysis of the C-index across the Binet A cohorts, the
1- and 5-year cumulative risk for treatment need, and number of
events per 100 person years, and bootstrapping was used to
calculate 95% CI. Heterogeneity was assessed by using the I2
statistic and Cochran’s Q test.
Results
Individual patient data from 11 cohorts of patients with early-
stage CLL initially managed with active surveillance were col-
lected, accounting for a total of 4933 patients (Tables 1 and 2). At
the time of treatment, Binet stage and/or indication for therapy
were consistent across the study cohorts and were similar to
those reported in first-line clinical trials (supplemental Table 1),
thus mitigating the risk for biases resulting from heterogeneity in
treatment initiation triggers.
By univariable analysis in the UEP training series, which reflects
patients managed in daily practice (N 5 333; median follow-up,
7.2 years; number of treatment events, 95), baseline factors
associated with an increased risk for treatment need (ie, TTFT)
with a Bonferroni corrected P value , .05 were palpable lymph
nodes, absolute lymphocyte count (.15 3 109/L), mild ane-
mia (hemoglobin between 10 and 13 g/dL in men and 10 and
12 g/dL in women), unmutated IGHV genes, and trisomy 12
(Figure 1A). Sensitivity analysis accounting for death without
treatment as competing risk confirmed the univariable associ-
ations between baseline variables and TTFT (supplemental
Table 2). By multivariable analysis in the training series, 4 vari-
ables independently associated with TTFT were identified, in-
cluding unmutated IGHV genes, absolute lymphocyte count
higher than 15 3 109/L, palpable lymph nodes, and trisomy 12
(Figure 1B). The elastic net approach confirmed the stability of
the selected variables, as the coefficients for unmutated IGHV
genes, absolute lymphocyte count higher than 15 3 109/L,
palpable lymph nodes, and trisomy 12 were not penalized and
therefore not shrunk to zero. Unmutated IGHV genes, absolute
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lymphocyte count higher than 15 3 109/L, and palpable lymph
nodes, but not trisomy 12, were found to be the most stable
biomarkers after iterating the multivariable analysis in each
single-validation Binet A cohort (Figure 1C). Across the valida-
tion cohorts, unmutated IGHV genes, absolute lymphocyte
count higher than 15 3 109/L, and palpable lymph nodes
maintained the highest percentage of selection in the final
model, as well as after including in the multivariable analyses
del(17p) and elevated b-2-microglobulin, which are part of the
CLL-IPI score (Figure 1D).18
After pruning the model from the less consistent covariates,
unmutated IGHV genes, absolute lymphocyte count higher than
15 3 109/L, and palpable lymph nodes were used to build the
score and received a weight of 1 because of similar regression
coefficients (Figure 1B). The hierarchical order of the sum of the
scores in prognosticating TTFT was established by recursive
partitioning analysis. This approach allowed us to establish the
final international prognostic score to classify patients with
asymptomatic CLL in early-stage disease (International Prog-
nostic Score for Early-stage CLL [IPS-E]) according to the risk
for treatment need. Patients with a score of 0 had the longest
TTFT, and patients with a score of 2 or 3 had the shortest TTFT,
whereas patients with a score of 1 had an intermediate TTFT
(supplemental Figure 2).
Patients from the training cohort were segregated into 3 distinct
risk categories according to the IPS-E (Figure 2A): low (score 0),
A
Unmutated IGHV
Trisomy 12
Palpable lymph nodes
Hb <13 g/dL (M)/<12 g/dL (F)
Lymphocytes >15x109/L
ATM mutation
Del(11q)
SF3B1 mutation
Palpable spleen
B2M >3.5 mg/L
NOTCH1 mutation
Del(17p)
Platelets <150x109/L
Male gender
Age >65
TP53 mutation
MYD88 mutation
FISH normal
Del(13q)
Hazard ratio
0 1 2 3 4 5 6
-log10 q-value
0 5 10
B
Unmutated IGHV
Palpable lymph nodes
Lymphocytes >15x109/L
Trisomy 12
Hb <13 g/dL (M)/<12 g/dL (F)
Hazard ratio
0 1 2 3 4 5 6
-log10 p-value
0 5 10
D
Unmutated IGHV
Lymphocytes >15x109/L
Palpable lymph nodes
Del(17p)
B2M >3.5 mg/L
0% 25% 50% 75% 100%
Percentage of selection
C
Unmutated IGHV
Lymphocytes >15x109/L
Palpable lymph nodes
Trisomy 12
0% 25% 50% 75% 100%
Percentage of selection
Figure 1. Univariable and multivariable analysis for time to
first treatment. (A) Forest plot of the hazard ratio for the 19
covariates assessed for association with TTFT by univariable
analysis. Solid boxes indicate the hazard ratio, horizontal lines
indicate the 95% CIs. The red dot line marks hazard ratio of 1. The
bar graph on the left shows themultiplicity adjusted -log10 P value
by Bonferroni. The red solid line marks the .05 significance level.
(B) Forest plot of the hazard ratio for the 5 covariates assessed for
association with TTFT by multivariable analysis. Solid boxes in-
dicate the hazard ratio, horizontal lines indicate the 95% CIs. The
red dot line marks hazard ratio of 1. The bar graph on the left
shows the -log10 P value. The red solid line marks the .05 sig-
nificance level. (C-D) The bar plot shows the percentage of
covariate selection in the final multivariable model across the 9
Binet A validation cohorts. The red line indicates the threshold
selected as inclusion criteria in the final model.
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intermediate (score 1), and high (score 2-3) risk. Sensitivity
analysis accounting for death before treatment as competing risk
consistently confirmed that IPS-E discriminates 3 risk groups with
significantly different TTFT (supplemental Figure 3A). The ability
of the IPS-E in discriminating TTFT (C-index) was 0.74 (Figure 3).
We validated the IPS-E, using 9 different independent series of
patients with Binet stage A CLL. Some heterogeneity across the
study cohorts allowed us to robustly confirm the external validity
and generalizability of IPS-E irrespective of the case mix of the
population. Heterogeneity in the baseline features reflected
the source of the cohort; namely, population-based (SCAN:
N 5 223; median follow-up, 12.9 years; number of treatment
events, 104) vs primary care institutions (Barcelona: N 5 355;
median follow-up, 10.3 years; number of treatment events, 155;
Southampton: N5 226; median follow-up, 6.6 years; number of
treatment events, 80; Sapienza University: N 5 223; median
follow-up, 11.3 years; number of treatment events, 117) vs re-
ferral centers (M.D. Anderson Cancer Center: N5 1225; median
follow-up, 5.2 years; number of treatment events, 357; Brno:
N 5 269; median follow-up, 7.7 years; number of treatment
events, 135) vs clinical trials (CLL1: N 5 547; median follow-up,
8.3 years; number of treatment events, 229; CLL7: N 5 339;
median follow-up, 4.2 years; number of treatment events, 75;
O-CLL-1: N 5 312; median follow-up, 7.5 years; number of
treatment events, 136). The IPS-E was confirmed and the 3 risk
groups with significantly different TTFT were reproduced in
the independent validation series both by primary analysis
(Figure 2B; supplemental Figure 4A-I) and by sensitivity
analysis, accounting for death before treatment as compet-
ing risk (supplemental Figure 3B-J). By meta-analysis across
the cohorts, the IPS-E C-index for TTFT was 0.70 (Figure 3),
whereas the C-index of the sole IGHVmutation status was 0.67
(95% CI, 0.66-0.68; supplemental Figure 5). Approaching the
same meta-analytic assessment across the study cohorts,
IPS-E showed a slightly higher discrimination capacity of TTFT
compared with CLL-IPI (C-index, 0.68; 95% CI, 0.67-0.70;
supplemental Figure 6).
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Figure 2. IPS-E stratified TTFT in patients with early-stage CLL managed with active surveillance. (A) Kaplan-Meier curves of TTFT stratified by IPS-E in the UEP discovery
cohort. (B) Meta-analytic estimate of TTFT by IPS-E and the corresponding variability across the 9 Binet A validation cohorts. The bold line shows the cubic spline fitted on the
meta-analytic estimate of the cumulative proportion of TTFT at each point. The shadow shows the cubic splines fitted on the meta-analytic estimate of the 95% CI of the
cumulative proportion of TTFT at each point. (C) Kaplan-Meier curves of TTFT stratified by IPS-E in the Mayo Clinic validation cohort. Blue, low risk; green, intermediate risk; red,
high risk by IPS-E. Multiplicity corrected P values by pairwise log-rank tests are shown.
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The training and validation series weremeta-analyzed to provide
amore precise estimate of the risk for treatment need in each risk
group (Figure 4). Low-risk patients overall corresponded to
29.5% of cases across the 10 Binet stage A CLL cohorts. Their
cumulative risk for treatment need (not accounting for death
resulting from competing risk) was less than 0.1% after 1 year of
surveillance, and 8.4% after 5 years. The risk for treatment was
2.0 events per 100 person years among low-risk patients.
Intermediate-risk patients overall corresponded to 36.2% of
cases across the 10 Binet stage A CLL cohorts. Their cumulative
risk for treatment need (not accounting for death resulting from
competing risk) was 3.1% after 1 year of surveillance, and 28.4%
after 5 years. The need for therapy was 6.1 events per 100 person
years among intermediate-risk patients. High-risk patients
overall corresponded to 34.3% of cases across the 10 validation
cohorts. Their cumulative risk for treatment need (not accounting
for death resulting from competing risk) was 14.1% after 1 year of
surveillance and 61.2% after 5 years. The risk for treatment was
16.1 events per 100 person years among high-risk patients. IPS-E
performed equivalently over sequential periods, which is con-
sistent with the lack of updates of treatment initiation criteria in
the guidelines3-5,21 and the steadiness of the threshold for
commencement of therapy adopted over time by the physicians
(supplemental Figure 7).
Two different clinical staging systems are used to stratify patients
with CLL; namely, Binet staging, mostly used in European
countries, and Rai staging, mostly used in the United States. We
aimed at validating the IPS-E also in patients with early-stage CLL
defined according to the Rai system (stage 0, I, and II) and
managed with active surveillance (Mayo Clinic cohort: N5 881).
The 3 IPS-E risk groups were well segregated both in the primary
analysis (Figure 2C) and in the sensitivity analysis, accounting for
death before treatment as competing risk (supplemental
Figure 3K), thus confirming the generalizability of IPS-E also in
patients with CLL staged according to the Rai system.
Discussion
The majority of patients with CLL are diagnosed in asymp-
tomatic, early phases of the disease and are followed with no
therapy.1,12 The clinical evolution of these patients is hetero-
geneous and difficult to predict. Although some patients display
a quiescent disease never requiring therapy, others present
active disease shortly after diagnosis and require intervention.
Despite the general improvement on the outcome of patients
with CLL, the relative survival of early-stage patients (ie, Binet
stage A) has not significantly changed during the last decades.2
Themanagement of these patients constitutes amajor challenge
and should be made on the basis of the best possible evidence
and a risk-tailored policy.
There are several prognostic models that can be used to sep-
arate patients with different outcome within the whole pop-
ulation of subjects with CLL.14,18,19,35-40 However, in most of these
models, the outcome of patients with early-stage CLL is either
not analyzed nor investigated as a unique subgroup, and
asymptomatic patients are not separately investigated. More-
over, in most such models, overall survival is the main end
point.18,19 The uniqueness of patients with CLL diagnosed with
asymptomatic early disease and the challenges posed by their
management make advisable a specific prognostic model with
TTFT as a main end point.
An important general caveat is that outcome indicators derived
from patients requiring therapy do not necessarily apply to
patients not requiring intervention. Among patients with CLL
managed with active surveillance, the IGHV unmutated status is
the biomarker with the strongest effect on TTFT prognostication.
In contrast, other recurrent molecular features associated with
inferior overall survival such as TP53 abnormalities, ATM ab-
normalities, andNOTCH1mutations did not enter into the IPS-E
model. Patients harboring TP53 aberrations, but mutated IGHV
genes,may have a prolongedTTFT and a relatively benign clinical
course under observation.41-43 Patients having ATM abnormalities
or NOTCH1mutations are highly enriched with unmutated IGHV
genes. However, a large proportion of IGHV unmutated patients
does not harbor ATM abnormalities or NOTCH1 mutation.41-46
Therefore, IGHV unmutated status not only captures ATM and
NOTCH1 abnormalities but also expands its prognostic infor-
mation to cases lacking these unfavorable genetic lesions.
The IPS-E presented in this study is a robust prognostic tool
based on routine clinical and laboratory variables that informs at
the time of diagnosis about the probability that a given patient
with CLL in early-stage disease progresses and needs treatment.
The cumulative risk for need of treatment after 1 and 5 years of
observation was 14.1% and 61.2%, respectively, for an IPS-E
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high-risk patient, whereas it was 2.1% and 28.4%, for intermediate-
risk patients and less than 0.1% and 8.4% for low-risk patients.
Against this backdrop, IPS-E high-risk patients should be followed
more closely than low- and intermediate-risk patients because of
the likelihood of requiring treatment sooner.
IPS-E calculation is simple, being the sumof 3 variables. Compared
with other scores, IPS-E calculation needs the assessment of only 1
molecular variable; namely, the IGHVmutation status, the testing of
which is broadly available and standardized. IGHV status has been
recognized by the current guidelines as a predictive biomarker for
treatment tailoring.5,22,47 Our results further support the indication
for testing IGHVmutations in patients with CLL.Moreover, as IGHV
status never changes during the course of disease, it might be
evaluated at the time of first diagnosis to provide an estimate of
TTFT to the patient and to the treating physician. The results of our
study also support that, as recommended by guidelines, FISH
analysis and molecular testing for TP53 has no clinical utility when
performed at CLL presentation in early-stage asymptomatic pa-
tients. TP53 abnormalities have a predictive role at time of therapy,
but no prognostic role in an early-stage setting when determining
TTFT. Also, they can change during the course of disease.
Therefore, TP53 status may not be routinely evaluated in early-
stage asymptomatic patients lacking treatment indication (in line
with the iwCLL criteria and CLL guidelines).3-5,21 CLL can exhibit
diverse growth patterns, including a continued stable state, never
requiring therapy after diagnosis.48,49 However, a short lymphocyte
doubling time is rarely an indication to start therapy by itself, as
shown in previous reports50 and in this study, and therefore was not
included as a variable for developing IPS-E.
The simplicity of IPS-E should facilitate its translation to the clinic.
The IPS-E could help physicians, medical care providers, and
health authorities in their strategies and resources allocation.
Likewise, such a prognostic model could be useful to design
clinical trials for patients with high-risk, early-stage CLL, an issue
that has gained momentum because of the availability of ef-
fective small molecules with manageable toxicity.51,52
The development of the IPS-E followed an extensively used ap-
proach for the generation of prognostic scores in hematology.18,53-56
However, the risk for biases related to the timing of scheduled
evaluations and premature censoring cannot be discarded. In
contrast, although the IPS-E has an outcome discrimination capacity
that is generally considered as acceptable57 and similar to that of
other CLL prognostication scores now used in clinical practice and
for clinical trial design,18 it can be eventually improved. Therefore,
the IPS-E warrants prospective evaluation and can be regarded as a
building block to which newly discovered independent outcome
predictors for patients with early-stage CLL could be added.
Acknowledgments
This study was supported by Swiss Cancer League, ID HSR-4660-11-
2018, Bern, Switzerland; Research Advisory Board of the Ente Ospe-
daliero Cantonale, Bellinzona, Switzerland; European Research Council
Consolidator Grant CLLCLONE ID: 772051; Grant No. 320030_169670/1
Swiss National Science Foundation, Berne, Switzerland; Fondazione
Fidinam, Lugano, Switzerland; Nelia & Amadeo Barletta Foundation,
Lausanne, Switzerland; Fond’Action, Lausanne, Switzerland; Translational
Research Program, No. 6594-20, The Leukemia & Lymphoma Society, New
York; AIRC5x1000,No. 21198, Associazione Italiana per la Ricerca sul Cancro
Foundation, Milan, Italy; PRIN 2017 No. 2015ZMRFEA_004, MIUR, Rome,
Italy; Italian Ministry of Health 5x1000 funds 2014 and 2016, Compagnia
S. Paolo Turin Italy, project 2017.0526; Swedish Cancer Society, Swedish
Research Council, Knut and Alice Wallenberg Foundation, Karolinska Insti-
tutet, Karolinska University Hospital, and Radiumhemmets Forskningsfonder,
Stockholm, Sweden; andMHCRgrants No. NV19-03-00091 andDROFNBr,
65269705, MEYS CR under the project CEITEC 2020 (LQ1601).
Authorship
Contribution: A.C. and L.T.d.B. performed statistical analysis, interpreted
data, and wrote the manuscript; P.L., M. A. Hoechstetter, C.D.H., L.D.P.,
J.D., K.G.R., M. Gentile, M.D., F.R.M., G. Chiodin, M.M., J.B., J.K., K.E.S.,
R.M., M. A. Hess, and T.S.B. provided clinical data and contributed to
manuscript revision; G. Cutrona, C.D., V.S., A.B., and A.N. contributed to
molecular studies and manuscript revision; W.W., E.B., B.G., E.Z., S.G.,
M. Ghielmini, F.C., G.S., M.F., R.R., F.F., R.F., S.P., F.M., S.S., and H.D.
contributed to manuscript revision; S.A.P., W.G.W., E.M., G.G., and M.H.
provided key scientific insights and contributed to study design, data
interpretation, and manuscript revision; and D.R. designed the study,
interpreted data, and wrote the manuscript.
Conflict-of-interest disclosure: D.R. received honoraria from AbbVie,
AstraZeneca, Gilead, Janssen, and Roche, and research grants from
AbbVie, Gilead, Janssen, and Cellestia. M. Hallek received research sup-
port and honoraria from Roche, Gilead, Mundipharma, Janssen, Celgene,
Pharmacyclics, andAbbVie.G.G. receivedhonoraria fromAbbVie, Janssen,
AstraZeneca, and Sunesis. G.S. received honoraria from Celgene and
Gilead. S.A.P. received research funding (to the institution) from Pharma-
cyclics, MorphoSys, Janssen, AstraZeneca, and Ascentage Pharma for
clinical studies andhonoraria fromPharmacyclics, AstraZeneca,Genentech,
Gilead, and AbbVie (all to the institution). R.R. received honoraria from
Illumina, Roche, Janssen, and AbbVie. R.F. received honoraria from
AbbVie, Janssen, Amgen, Novartis, and AstraZeneca. F.F. received
honoraria from Janssen-Cilag, and AbbVie, and a research grant from
Gilead. C.D.H. received travel support and research funding from Roche.
G. Cutrona received a research grant from Gilead (fellowship program
2017). The remaining authors declare no competing financial interests.
ORCID profiles: K.G.R., 0000-0002-7313-1875; G. Chiodin, 0000-0002-
1456-8997; G. Cutrona, 0000-0002-3335-1101; B.G., 0000-0001-5418-
0949; E.Z., 0000-0002-5522-6109; A.N., 0000-0001-9047-5912; F.F.,
0000-0002-2211-1831; S.P., 0000-0001-7136-2680; F.M., 0000-0002-
2585-7073; S.A.P., 0000-0002-3221-7314.
Correspondence: Davide Rossi, Department of Hematology, Oncology
Institute of Southern Switzerland, Via Ospedale, 6500 Bellinzona, Swit-
zerland; e-mail: davide.rossi@eoc.ch.
Footnotes
Submitted 23 September 2019; accepted 12 February 2020; prepub-
lished online on Blood First Edition 8 April 2020. DOI 10.1182/blood.
2019003453.
*A.C., L.T.d.B., P.L., and M. A. Hoechstetter contributed equally to
this study.
†S.A.P., W.G.W., E.M., G.G., M.H., and D.R. contributed equally to
this study.
Presented at the 15th International Conference onMalignant Lymphoma,
Lugano, Switzerland, 18-22 June 2019.
Please e-mail the corresponding author for original data.
The online version of this article contains a data supplement.
There is a Blood Commentary on this article in this issue.
The publication costs of this article were defrayed in part by page charge
payment. Therefore, and solely to indicate this fact, this article is hereby
marked “advertisement” in accordance with 18 USC section 1734.
CLL IPS-E blood® 21 MAY 2020 | VOLUME 135, NUMBER 21 1867
D
ow
nloaded from
 https://ashpublications.org/blood/article-pdf/135/21/1859/1731550/bloodbld2019003453.pdf by guest on 22 M
ay 2020
REFERENCES
1. Teras LR, DeSantis CE, Cerhan JR, Morton LM,
Jemal A, Flowers CR. 2016 US lymphoid
malignancy statistics by World Health Orga-
nization subtypes. CA Cancer J Clin. 2016;
66(6):443-459.
2. Abrisqueta P, Pereira A, Rozman C, et al.
Improving survival in patients with chronic
lymphocytic leukemia (1980-2008): the Hos-
pital Clinic of Barcelona experience. Blood.
2009;114(10):2044-2050.
3. Cheson BD, Bennett JM, Grever M, et al.
National Cancer Institute-sponsored Working
Group guidelines for chronic lymphocytic
leukemia: revised guidelines for diagnosis and
treatment. Blood. 1996;87(12):4990-4997.
4. Hallek M, Cheson BD, Catovsky D, et al; In-
ternational Workshop on Chronic Lympho-
cytic Leukemia. Guidelines for the diagnosis
and treatment of chronic lymphocytic leuke-
mia: a report from the International Workshop
on Chronic Lymphocytic Leukemia updating
the National Cancer Institute-Working Group
1996 guidelines. Blood. 2008;111(12):
5446-5456.
5. Eichhorst B, Robak T, Montserrat E, et al.
Chronic lymphocytic leukaemia: ESMO Clini-
cal Practice Guidelines for diagnosis, treat-
ment and follow-up. Ann Oncol. 2015;
26(Suppl 5):v78-v84.
6. Shustik C, Mick R, Silver R, Sawitsky A, Rai K,
Shapiro L. Treatment of early chronic lym-
phocytic leukemia: intermittent chlorambucil
versus observation.Hematol Oncol. 1988;6(1):
7-12.
7. Dighiero G, Maloum K, Desablens B, et al;
French Cooperative Group on Chronic Lym-
phocytic Leukemia. Chlorambucil in indolent
chronic lymphocytic leukemia. N Engl J Med.
1998;338(21):1506-1514.
8. Schweighofer CD, Cymbalista F, Mu¨ller C,
et al. Early versus deferred treatment with
combined fludarabine, cyclophosphamide
and rituximab (FCR) improves event-free sur-
vival in patients with high-risk Binet stage A
chronic lymphocytic leukemia – first results of
a randomized German-French Cooperative
Phase III Trial. Blood. 2013;122(21):524.
9. Hoechstetter MA, Busch R, Eichhorst B, et al.
Early, risk-adapted treatment with fludarabine
in Binet stage A chronic lymphocytic leukemia
patients: results of the CLL1 trial of the Ger-
man CLL study group. Leukemia. 2017;31(12):
2833-2837.
10. Chemotherapeutic options in chronic lym-
phocytic leukemia: a meta-analysis of the
randomized trials. CLL Trialists’ Collaborative
Group. J Natl Cancer Inst. 1999;91(10):
861-868.
11. Hallek M, Shanafelt TD, Eichhorst B. Chronic
lymphocytic leukaemia. Lancet. 2018;
391(10129):1524-1537.
12. Sant M, Allemani C, Tereanu C, et al;
HAEMACARE Working Group. Incidence
of hematologic malignancies in Europe
by morphologic subtype: results of the
HAEMACARE project. Blood. 2010;116(19):
3724-3734.
13. Langerbeins P, Bahlo J, Rhein C, et al. Ibrutinib
versus placebo in patients with asymptomatic,
treatment-naı¨ve early stage CLL: primary
endpoint results of the phase 3 double-blind
randomized CLL12 trial. Hematol Oncol.
2019;37(S2):38-40.
14. Wierda WG, O’Brien S, Wang X, et al.
Multivariable model for time to first treatment
in patients with chronic lymphocytic leukemia.
J Clin Oncol. 2011;29(31):4088-4095.
15. Molica S, Giannarelli D, Gentile M, et al.
External validation on a prospective basis of a
nomogram for predicting the time to first
treatment in patients with chronic lymphocytic
leukemia. Cancer. 2013;119(6):1177-1185.
16. Mansouri L, Cahill N, Gunnarsson R, et al.
NOTCH1 and SF3B1 mutations can be added
to the hierarchical prognostic classification in
chronic lymphocytic leukemia. Leukemia.
2013;27(2):512-514.
17. Rossi D, Rasi S, Spina V, et al. Integrated
mutational and cytogenetic analysis identifies
new prognostic subgroups in chronic lym-
phocytic leukemia. Blood. 2013;121(8):
1403-1412.
18. International CLL-IPI working group. An in-
ternational prognostic index for patients with
chronic lymphocytic leukaemia (CLL-IPI): a
meta-analysis of individual patient data.
Lancet Oncol. 2016;17(6):779-790.
19. Delgado J, Doubek M, Baumann T, et al.
Chronic lymphocytic leukemia: A prognostic
model comprising only two biomarkers (IGHV
mutational status and FISH cytogenetics)
separates patients with different outcome and
simplifies the CLL-IPI. Am J Hematol. 2017;
92(4):375-380.
20. McShane LM, Altman DG, SauerbreiW, Taube
SE, Gion M, Clark GM; Statistics Sub-
committee of the NCI-EORTCWorking Group
on Cancer Diagnostics. Reporting recom-
mendations for tumor marker prognostic
studies (REMARK). J Natl Cancer Inst. 2005;
97(16):1180-1184.
21. Hallek M, Cheson BD, Catovsky D, et al. iwCLL
guidelines for diagnosis, indications for
treatment, response assessment, and sup-
portive management of CLL. Blood. 2018;
131(25):2745-2760.
22. Bain BJ. Ethnic and sex differences in the total
and differential white cell count and platelet
count. J Clin Pathol. 1996;49(8):664-666.
23. Damle RN, Wasil T, Fais F, et al. Ig V gene
mutation status and CD38 expression as novel
prognostic indicators in chronic lymphocytic
leukemia. Blood. 1999;94(6):1840-1847.
24. Hamblin TJ, Davis Z, Gardiner A, Oscier DG,
Stevenson FK. Unmutated Ig V(H) genes are
associated with a more aggressive form of
chronic lymphocytic leukemia. Blood. 1999;
94(6):1848-1854.
25. Beutler E, Waalen J. The definition of anemia:
what is the lower limit of normal of the blood
hemoglobin concentration? Blood. 2006;
107(5):1747-1750.
26. Rossi D, Condoluci A, Spina V, Gaidano G.
Methods for measuring ctDNA in lymphomas.
Methods Mol Biol. 2019;1881:253-265.
27. Kaplan EL, Meier P. Nonparametric estimation
from incomplete observations. J Am Stat
Assoc. 1958;53(282):457-481.
28. Thabane L, Mbuagbaw L, Zhang S, et al. A
tutorial on sensitivity analyses in clinical trials:
the what, why, when and how. BMC Med Res
Methodol. 2013;13(1):92.
29. Dignam JJ, Kocherginsky MN. Choice and
interpretation of statistical tests used when
competing risks are present. J Clin Oncol.
2008;26(24):4027-4034.
30. Cox DR. Regression models and life tables. J R
Stat Assoc. 1972;34:187-220.
31. Simon N, Friedman J, Hastie T, Tibshirani R.
Regularization paths for Cox’s proportional
hazards model via coordinate descent. J Stat
Softw. 2011;39(5):1-13.
32. Schoenfeld D. Partial residuals for the
proportional hazard regression model.
Biometrika. 1982;69(1):239-241.
33. Ciampi A, Negassa A, Lou Z. Tree-structured
prediction for censored survival data and the
Cox model. J Clin Epidemiol. 1995;48(5):
675-689.
34. Harrell FE Jr. Regression modeling strategies.
New York, NY: Springer-Verlag; 2001.
35. Rai KR, Sawitsky A, Cronkite EP, Chanana AD,
Levy RN, Pasternack BS. Clinical staging of
chronic lymphocytic leukemia. Blood. 1975;
46(2):219-234.
36. Wierda WG, O’Brien S, Wang X, et al.
Prognostic nomogram and index for overall
survival in previously untreated patients with
chronic lymphocytic leukemia. Blood. 2007;
109(11):4679-4685.
37. Pflug N, Bahlo J, Shanafelt TD, et al.
Development of a comprehensive prognostic
index for patients with chronic lymphocytic
leukemia. Blood. 2014;124(1):49-62.
38. Gentile M, Shanafelt TD, Cutrona G, et al. A
progression-risk score to predict treatment-
free survival for early stage chronic lympho-
cytic leukemia patients. Leukemia. 2016;30(6):
1440-1443.
39. Molica S, Giannarelli D, Mirabelli R, et al.
Reliability of six prognostic models to predict
time-to-first-treatment in patients with chronic
lymphocytic leukaemia in early phase. Am
J Hematol. 2017;92(6):E91-E93.
40. Montserrat E, Gale RP. Predicting the out-
come of patients with chronic lymphocytic
leukemia: Progress and uncertainty. Cancer.
2019;125(21):3699-3705.
41. Best OG, Gardiner AC, Davis ZA, et al. A
subset of Binet stage A CLL patients with
TP53 abnormalities and mutated IGHV genes
have stable disease. Leukemia. 2009;23(1):
212-214.
42. Tam CS, Shanafelt TD, Wierda WG, et al. De
novo deletion 17p13.1 chronic lymphocytic
leukemia shows significant clinical heteroge-
neity: the M. D. Anderson and Mayo Clinic
experience. Blood. 2009;114(5):957-964.
43. Hu B, Patel KP, Chen HC, et al. Association of
gene mutations with time-to-first treatment in
384 treatment-naive chronic lymphocytic
leukaemia patients. Br J Haematol. 2019;
187(3):307-318.
44. Nadeu F, Delgado J, Royo C, et al. Clinical
impact of clonal and subclonal TP53, SF3B1,
BIRC3, NOTCH1, and ATM mutations in
1868 blood® 21 MAY 2020 | VOLUME 135, NUMBER 21 CONDOLUCI et al
D
ow
nloaded from
 https://ashpublications.org/blood/article-pdf/135/21/1859/1731550/bloodbld2019003453.pdf by guest on 22 M
ay 2020
chronic lymphocytic leukemia. Blood. 2016;
127(17):2122-2130.
45. Montserrat E, Bauman T, Delgado J. Present
and future of personalized medicine in CLL.
Best Pract Res Clin Haematol. 2016;29(1):
100-110.
46. Baliakas P, Hadzidimitriou A, Sutton LA, et al;
European Research Initiative on CLL (ERIC).
Recurrent mutations refine prognosis in
chronic lymphocytic leukemia. Leukemia.
2015;29(2):329-336.
47. Wierda WG, Byrd JC, Abramson JS, et al.
NCCN Guidelines Insights: Chronic Lympho-
cytic Leukemia/Small Lymphocytic Lym-
phoma, Version 2.2019. J Natl Compr Canc
Netw. 2019;17(1):12-20.
48. Gruber M, Bozic I, Leshchiner I, et al. Growth
dynamics in naturally progressing chronic
lymphocytic leukaemia. Nature. 2019;
570(7762):474-479.
49. Montserrat E, Sa´nchez-Bisono´ J, Viñolas N,
RozmanC. Lymphocyte doubling time in chronic
lymphocytic leukaemia: analysis of its prognostic
significance. Br J Haematol. 1986;62(3):567-575.
50. Mozas P, Rivas-Delgado A, Baumann T, et al.
Analysis of criteria for treatment initiation in
patients with progressive chronic lymphocytic
leukemia. Blood Cancer J. 2018;8(1):10.
51. Sharma S, Rai KR. Chronic lymphocytic leu-
kemia (CLL) treatment: So many choices,
such great options. Cancer. 2019;125(9):
1432-1440.
52. Hallek M, Fu¨rstenau M. How to approach CLL
in clinical practice. Hematol Oncol. 2019;
37(Suppl 1):38-42.
53. International Non-Hodgkin’s Lymphoma
Prognostic Factors Project. A predictive
model for aggressive non-Hodgkin’s
lymphoma. N Engl J Med. 1993;329(14):
987-994.
54. Solal-Ce´ligny P, Roy P, Colombat P, et al.
Follicular lymphoma international prog-
nostic index. Blood. 2004;104(5):
1258-1265.
55. Federico M, Bellei M, Marcheselli L, et al.
Follicular lymphoma international prognostic
index 2: a new prognostic index for
follicular lymphoma developed by the in-
ternational follicular lymphoma prognostic
factor project. J Clin Oncol. 2009;27(27):
4555-4562.
56. Hoster E, Dreyling M, Klapper W, et al;
European Mantle Cell Lymphoma Network.
A new prognostic index (MIPI) for
patients with advanced-stage mantle
cell lymphoma. Blood. 2008;111(2):
558-565.
57. Hosmer DW, Lemeshow S. Applied logistic
regression. 2nd ed. New York: John Wiley &
Sons; 2000.
CLL IPS-E blood® 21 MAY 2020 | VOLUME 135, NUMBER 21 1869
D
ow
nloaded from
 https://ashpublications.org/blood/article-pdf/135/21/1859/1731550/bloodbld2019003453.pdf by guest on 22 M
ay 2020
